HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Industry News Roundup: Earnings, User Fee Webinar, UK Ad Enforce

This article was originally published in The Pink Sheet

Executive Summary

Sensodyne shines for Glaxo-Novartis JV; and international growth leads Prestige Brands OTCs.

You may also be interested in...



OTC Monograph User Fees: FDA-Industry Talks Move From Basics To Details

CDER officials and industry met in July to discuss "the ground rules governing the OTC monograph user fee." CHPA CEO Scott Melville cautions: "No one is going to rush into an agreement that we're going to have to live with for decades."

Health & Wellness Industry Roundup: July 11-15

Compromise GMO legislation passes House; private equity looks for health, wellness investments, including China; and more news in brief.

Moberg Sustains Derma Drive, Acquires Prestige Brands' New Skin

The Swedish firm pays $40m for the PediaCare and Fiber Choice brands in addition to New Skin Liquid Bandages, which are available in spray and liquid delivery and are "the main profitability contributor in the acquired portfolio," says CEO Peter Wolpert.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS123099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel